PMID- 33241490
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20221108
IS  - 1937-5395 (Electronic)
IS  - 1937-5387 (Linking)
VI  - 14
IP  - 3
DP  - 2021 Jun
TI  - NRF2 in Cardiovascular Diseases: a Ray of Hope!
PG  - 573-586
LID - 10.1007/s12265-020-10083-8 [doi]
AB  - Heart failure is a worldwide pandemic influencing 26 million individuals 
      worldwide and is expanding. Imbalanced redox homeostasis in cardiac cells alters 
      the structure and function of the cells, which leads to contractile dysfunction, 
      myocardial hypertrophy, and fibrosis in chronic heart failure. Various targets 
      and agents acting on these such as siRNA, miRNA, interleukin-1, opioids, 
      vasodilators, and SGLT2 inhibitors are being evaluated for heart failure, and 
      nuclear factor erythroid 2-related factor 2 (NRF2) is one of them. NRF2 is a 
      master transcription factor which is expressed in most of the tissues and 
      exhibits a major role in amplification of the antioxidant pathways associated 
      with the enzymes present in myocardium. Increased ROS generation and PI3K-Akt 
      signaling can activate the receptor NRF2. Various in vitro and in vivo and few 
      clinical studies suggested NRF2 may possess a potential for targeting oxidative 
      stress-induced cardiovascular diseases including heart failures. All these 
      studies collectively propose that upregulation of NRF2 will attenuate the 
      increase in hemodynamic stress and provide beneficial role in cardiovascular 
      diseases. The current review shall familiarize readers about the regulations and 
      functions of NRF2. We have also discussed the current evidences suggesting 
      beneficial role of NRF2 activators in heart failure. Graphical abstract.
FAU - Vashi, Ruju
AU  - Vashi R
AD  - Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad, 
      Gujarat, 382481, India.
FAU - Patel, Bhoomika M
AU  - Patel BM
AUID- ORCID: 0000-0003-0594-5452
AD  - Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad, 
      Gujarat, 382481, India. drbhoomikampatel@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201125
PL  - United States
TA  - J Cardiovasc Transl Res
JT  - Journal of cardiovascular translational research
JID - 101468585
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
SB  - IM
MH  - Animals
MH  - Gene Expression Regulation
MH  - Heart Diseases/genetics/*metabolism/pathology/physiopathology
MH  - Hemodynamics
MH  - Humans
MH  - Myocytes, Cardiac/*metabolism/pathology
MH  - NF-E2-Related Factor 2/genetics/*metabolism
MH  - Recovery of Function
MH  - *Regeneration
MH  - Signal Transduction
MH  - Ventricular Remodeling
OTO - NOTNLM
OT  - Diabetic cardiomyopathy
OT  - Heart failure
OT  - Ischemic reperfusion injury
OT  - Keap-1
OT  - Myocardial infarction
OT  - NRF2
OT  - NRF2 activators
OT  - Oxidative stress
OT  - Reactive oxygen species (ROS)
EDAT- 2020/11/27 06:00
MHDA- 2022/02/03 06:00
CRDT- 2020/11/26 05:50
PHST- 2020/08/06 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
PHST- 2020/11/26 05:50 [entrez]
AID - 10.1007/s12265-020-10083-8 [pii]
AID - 10.1007/s12265-020-10083-8 [doi]
PST - ppublish
SO  - J Cardiovasc Transl Res. 2021 Jun;14(3):573-586. doi: 10.1007/s12265-020-10083-8. 
      Epub 2020 Nov 25.